Journal ArticleDOI
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study
Alessandro Parisi,Giampiero Porzio,Katia Cannita,Olga Venditti,Antonio Avallone,Roberto Filippi,Lisa Salvatore,Giampaolo Tortora,M. Ribelli,Olga Nigro,Fabio Gelsomino,Andrea Spallanzani,Valeria Zurlo,Silvana Leo,Emanuela Dell'Aquila,Fulgenzi Claudia,Pasquale Lombardi,Susana Roselló Keränen,Giacomo Aimar,Ilaria Depetris,Riccardo Giampieri,Cristina Morelli,Michele De Tursi,Nicola Tinari,Francesca Di Pietro,Federica De Galitiis,N. Zanaletti,Teresa Troiani,P. Vitale,Ingrid Garajová,Michele Ghidini,Gian Paolo Spinelli,Federica Zoratto,Michela Roberto,Debora Ierinò,Angelica Petrillo,Carla D'Orazio,Corrado Ficorella,Alessio Cortellini +38 more
TLDR
In this paper, the authors compared triplet-bevacizumab and doublet-EGFRi as first-line regimen in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC) treated in clinical practice at 22 Oncology Units from March 2012 to October 2020.About:
This article is published in Clinical Colorectal Cancer.The article was published on 2021-07-18. It has received 7 citations till now. The article focuses on the topics: FOLFIRI & Regimen.read more
Citations
More filters
Journal ArticleDOI
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
Alessandro Parisi,Alessio Cortellini,Alessio Cortellini,Olga Venditti,Roberto Filippi,Lisa Salvatore,Lisa Salvatore,Giampaolo Tortora,Giampaolo Tortora,Michele Ghidini,Olga Nigro,Fabio Gelsomino,Ina Valeria Zurlo,Claudia Angela Maria Fulgenzi,Pasquale Lombardi,Susana Rosello Keranen,Susana Rosello Keranen,Ilaria Depetris,Riccardo Giampieri,Cristina Morelli,Pietro Di Marino,Francesca Di Pietro,N. Zanaletti,P. Vitale,Ingrid Garajová,Gian Paolo Spinelli,Federica Zoratto,Michela Roberto,Angelica Petrillo,Giacomo Aimar,Leonardo Patruno,Carla D'Orazio,Corrado Ficorella,Claudio Ferri,Giampiero Porzio +34 more
TL;DR: In this article, the authors evaluated post-induction management following first-line anti-epidermal growth factor receptor (EGFR)-based doublet regimens in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC).
Journal ArticleDOI
Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis.
Alessandro Parisi,Michele Ghidini,Riccardo Giampieri,Gianluca Tomasello,Andrea Luciani,Claudio Ferri,Rossana Berardi,Fausto Petrelli +7 more
TL;DR: A systematic review and metanalysis of randomized clinical trials (RCTs) investigating the efficacy of post-induction strategies after the first-line treatment with anti-Epidermal Growth Factor Receptor (EGFR) in patients with metastatic colorectal cancer (mCRC) are available as mentioned in this paper .
Journal ArticleDOI
Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
Veronica Zelli,Alessandro Parisi,Leonardo Patruno,Katia Cannita,Corrado Ficorella,Carla Luzi,Chiara Compagnoni,Francesca Zazzeroni,Edoardo Alesse,Alessandra Tessitore +9 more
TL;DR: Overall, this study case series adds evidence to the limited available literature concerning both the epidemiological and clinical aspects of CRC cases characterized by the presence of concurrent RAS/BRAF variants.
Journal ArticleDOI
Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study
Stefano Granieri,Christian Cotsoglou,A. Bonomi,Lisa Salvatore,Roberto Filippi,Olga Nigro,Fabio Gelsomino,Ina Valeria Zurlo,Ilaria Depetris,Riccardo Giampieri,Rossana Berardi,C. Morelli,Michele De Tursi,Michela Roberto,Elson Gjoni,Alessandro Germini,Nicola de’Angelis,Riccardo Memeo,Antonio Facciorusso,Ornella Garrone,Daryl Ramai,Michele Ghidini,Alessandro Parisi +22 more
TL;DR: In this paper, the authors explored the efficacy of a conversion strategy in a selected population of 272 left-sided RAS/BRAF wild-type colorectal cancer patients with liver-limited metastatic disease.
Journal ArticleDOI
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Paolo Antonetti,Maria Concetta Fargnoli,Giampiero Porzio,Lisa Salvatore,Lisa Salvatore,Roberto Filippi,Michele Ghidini,Olga Nigro,Fabio Gelsomino,Ina Valeria Zurlo,Emanuela Dell'Aquila,Pasquale Lombardi,Susana Roselló Keränen,Ilaria Depetris,Riccardo Giampieri,Cristina Morelli,Michele De Tursi,Francesca Di Pietro,N. Zanaletti,P. Vitale,Ingrid Garajová,Gian Paolo Spinelli,Federica Zoratto,Michela Roberto,Angelica Petrillo,Giacomo Aimar,Giacomo Aimar,Alessio Cortellini,Alessio Cortellini,Maria Vittoria Pensieri,Corrado Ficorella,Claudio Ferri,Alessandro Parisi +32 more
TL;DR: In this paper, the authors describe the management (pre-emptive or reactive) of anti-EGFR-related cutaneous adverse events (AEs), in a real-life clinical context, in a selected population of patients with left-sided, metastatic RAS/BRAF wild-type mCRC treated with doublet chemotherapy plus antiEGFR monoclonal antibody (i.e., panitumumab or cetuximab) as first-line regimen at 22 Institutions.
References
More filters
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies
TL;DR: An extensive series of Monte Carlo simulations were conducted to determine the optimal caliper width for estimating differences in means (for continuous outcomes) and risk differences (for binary outcomes).
Journal ArticleDOI
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem,Andrés Cervantes,René Adam,Alberto Sobrero,J.H.J.M. van Krieken,Dan Aderka,E. Aranda Aguilar,Alberto Bardelli,Al B. Benson,György Bodoky,Fortunato Ciardiello,André D'Hoore,Eduardo Díaz-Rubio,J.-Y. Douillard,Michel Ducreux,Alfredo Falcone,Axel Grothey,Thomas Gruenberger,Karin Haustermans,Volker Heinemann,Paulo M. Hoff,C.-H. Köhne,R. Labianca,Pierre Laurent-Puig,Brigette B.Y. Ma,Tim Maughan,Kei Muro,Nicola Normanno,Pia Österlund,Pia Österlund,Wim J.G. Oyen,Demetris Papamichael,George Pentheroudakis,Per Pfeiffer,Timothy J. Price,C.J.A. Punt,Jens Ricke,Arnaud Roth,R. Salazar,Werner Scheithauer,H.-J. Schmoll,Josep Tabernero,Julien Taieb,Sabine Tejpar,Harpreet Wasan,Takayuki Yoshino,Aziz Zaanan,Dirk Arnold +47 more
TL;DR: These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
Journal ArticleDOI
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini,Fotios Loupakis,Carlotta Antoniotti,Cristiana Lupi,Elisa Sensi,Sara Lonardi,Silvia Mezi,Gianluca Tomasello,Monica Ronzoni,Alberto Zaniboni,Giuseppe Tonini,Chiara Carlomagno,Giacomo Allegrini,Silvana Chiara,Mauro D'Amico,Cristina Granetto,Marina Cazzaniga,Luca Boni,Gabriella Fontanini,Alfredo Falcone +19 more
TL;DR: An updated analysis of the TRIBE study aimed to provide mature results for overall survival-a secondary endpoint-and report treatment efficacy in RAS and BRAF molecular subgroups, and assessed the secondary endpoint of overall survival in the main cohort.
Journal ArticleDOI
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Dirk Arnold,B. Lueza,J.-Y. Douillard,Marc Peeters,H. J. Lenz,Alan P. Venook,Volker Heinemann,E. Van Cutsem,Jean-Pierre Pignon,Josep Tabernero,Andrés Cervantes,Andrés Cervantes,Fortunato Ciardiello +12 more
TL;DR: A pooled analysis showed a worse prognosis for OS, PFS and ORR for patients with right-sided tumours in patients with RAS wt mCRC and a predictive effect of tumour side.